This content is for informational purposes only and does not constitute medical advice. Statements about dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary — consult your healthcare provider before starting any supplement. Full disclaimer
Evidence-Based Benefits
UTI prevention — Kranjčec et al. (2014) conducted a landmark RCT comparing 2g D-mannose daily vs nitrofurantoin vs no prophylaxis in 308 women with recurrent UTIs; D-mannose reduced recurrence by 85% and was comparable to the antibiotic group
Mechanism specificity — D-mannose specifically saturates FimH adhesin on type 1 fimbriae of E. coli, the lectin responsible for bladder cell attachment; this competitive inhibition is well-characterized in vitro and in vivo
Antibiotic stewardship — by reducing the need for prophylactic and repeated antibiotic courses, D-mannose helps address the growing problem of antibiotic-resistant uropathogens
Acute UTI support — while not a replacement for antibiotics in active infection, some evidence suggests D-mannose taken at higher doses (1.5g every 2 hours) may help resolve early-stage symptoms and support recovery
What the Research Says
D-Mannose has emerged as a promising non-antibiotic approach for preventing recurrent urinary tract infections (UTIs) in women. A pivotal randomized controlled trial (RCT) by Kranjčec et al. (2014) involving 308 women compared the efficacy of 2g daily D-mannose, 50mg nitrofurantoin, and no prophylaxis over six months. The study found that D-mannose reduced UTI recurrence from 60.8% in the no-prophylaxis group to 14.6%, comparable to the 20.4% recurrence rate with nitrofurantoin, while also demonstrating significantly fewer side effects.
The mechanism of action is well-established: Uropathogenic Escherichia coli (UPEC) type 1 fimbriae, equipped with FimH adhesins, bind to mannose on bladder uroplakin proteins. Excess mannose in the urine competitively blocks this adhesion, preventing bacterial colonization. This was further supported by a pilot study by Porru et al. (2014), which confirmed similar results using 1g D-mannose three times daily.
Recent systematic reviews and meta-analyses have provided additional insights. Vargas et al. (2025) conducted a systematic review and meta-analysis of six RCTs involving 1,167 participants, concluding that D-mannose did not significantly reduce recurrent UTI incidence compared to control or antibiotics. However, Lenger et al. (2020) found that D-mannose reduced recurrent UTIs in women compared to placebo, with a relative risk of 0.23. Kyriakides et al. (2021) also reported that D-mannose reduces recurrent UTI incidence and prolongs UTI-free periods based on eight studies involving 695 participants.
In addition, Singh et al. (2026) conducted a randomized, triple-blind, placebo-controlled study demonstrating that D-mannose supplementation improved urination-related UTI symptoms and reduced symptom bother compared to placebo after three days. Riemma et al. (2025) found that combining fosfomycin with a D-mannose supplement was more effective in reducing UTI episodes than either treatment alone.
Overall, while some studies suggest limited efficacy of D-mannose compared to antibiotics or control groups, others highlight its potential
RCTKranjčec B, Papeš D, Altarac S (2014). D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World Journal of Urology. DOIPubMed
Meta-analysisVargas CEF, Mutarelli A, Menegardo LG, Silva AKBD, et al. (2025). Efficacy of D-mannose as prophylaxis of recurrent urinary tract infection: a systematic review and meta-analysis of randomized controlled trials.. Jornal brasileiro de nefrologia. DOIPubMed
Meta-analysisLenger SM, Bradley MS, Thomas DA, Bertolet MH, et al. (2020). D-mannose vs other agents for recurrent urinary tract infection prevention in adult women: a systematic review and meta-analysis.. American journal of obstetrics and gynecology. DOIPubMed
ReviewCooper TE, Teng C, Howell M, Teixeira-Pinto A, et al. (2022). D-mannose for preventing and treating urinary tract infections.. The Cochrane database of systematic reviews. DOIPubMed
Kyriakides R, Jones P, Somani BK (2021). Role of D-Mannose in the Prevention of Recurrent Urinary Tract Infections: Evidence from a Systematic Review of the Literature.. European urology focus. DOIPubMed
Singh RG, Nguyen E, Zhao Y, Zhang C, et al. (2026). A randomized, triple-blind, placebo-controlled, parallel study of the efficacy of D-mannose for urinary tract infection symptoms in women.. Current urology. DOIPubMed
Riemma G, Vinci D, La Verde M, Caniglia FM, et al. (2025). Adding collagen, propolis plus quercetin, bacillus coagulans, hyaluronic acid and chondroitin sulphate to D-mannose avoids symptoms and prevents recurrence in women with recurrent urinary tract infections: a single-blind randomized controlled trial.. Expert review of anti-infective therapy. DOIPubMed
Show 4 more references
Wang J, Mei L, Wen H, Yang Y, et al. (2025). D-mannose enhances immune function and modulates gut microbiota composition in adult cats: A randomized controlled trial.. Research in veterinary science. DOIPubMed
Rau M, Santelli A, Martí S, Díaz MI, et al. (2024). Randomized clinical trial of non-antibiotic prophylaxis with d-Mannose plus Proanthocyanidins vs. Proanthocyanidins alone for urinary tract infections and asymptomatic bacteriuria in de novo kidney transplant recipients: The Manotras study.. Nefrologia. DOIPubMed
Kyzlasov P S, Neymark B A, Kuzmenko A V, Abuev G G, et al. (2024). [Experience with UroBest in patients with acute cystitis].. Urologiia (Moscow, Russia : 1999). PubMed
RCTSalvatore S, Ruffolo AF, Stabile G, Casiraghi A, et al. (2023). A Randomized Controlled Trial Comparing a New D-Mannose-based Dietary Supplement to Placebo for the Treatment of Uncomplicated Escherichia coli Urinary Tract Infections.. European urology focus. DOIPubMed
